CHICAGO, May 3, 2013 /PRNewswire/ -- Positron Corporation (OTCBB: POSC), a nuclear medicine healthcare company specializing in the field of cardiac Positron Emission Tomography (PET) imaging and high tech pharmacy automation, today announced a co-marketing agreement with Biologics Modular. Biologics Modular designs and manufacturers modular facilities that serve as self-contained biorepositories, biomanufacturing suites and research suites.
"As we look to accelerate PosiRx® adoption to markets both within and outside of the United States, this collaboration is an innovative way reach an expanded targeted audience," stated Positron's Chief Operating Officer Charles Conroy, RPh, MBA.
"PosiRx provides its users the ability to create patient specific unit doses in an ISO Class 5 environment and aids in compliance with USP 797 regulations. For those customers that need additional cleanroom capacity, such as pharmacies providing custom compounding of cancer treatment therapies, Biologics Modular has the most comprehensive and cost effective solution on the market today. By decreasing start-up time and reducing operational costs, the combined solution allows new markets to be serviced sooner, and more profitably, than previously possible," Conroy added.
"As cost pressures continue to drive the evolution of the U.S. pharmacy distribution model, providers are looking for new cost effective and readily implemented ways to service the nuclear medicine community," stated Clark H. Byrum Jr., Biologics Modular President and CEO. "By using Biologic Modular's pre-constructed and pre-tested modular units, our customers can lower capital expenditures and reduce development time in comparison to traditional brick and mortar alternatives. Pairing Biologics Modular's self-contained cleanroom with PosiRx's pharmacy automation allows our customers to control initial capital expenditures and ongoing operating costs better than their competition."
About Positron: Positron Corporation is a nuclear medicine healthcare company vertically integrating key segments of nuclear cardiologyproviding an end-to-end solution for cardiac PET. Through proprietary PET imaging systems, radiopharmaceuticals and radioisotopes solutions, Positron enables healthcare providers to more accurately diagnose disease and improve patient outcomes, while practicing cost effective medicine. Positron's unique products, market position and approach in securing the supply chain are substantial advantages, further accelerating the adoption of cardiac PET and growth of nuclear cardiology. Positron is redefining the industry. More information about Positron is available at www.positron.com.
About Biologics Modular: Biologics Modular designs, manufactures, and sells modular facilities to serve as self-contained biorepositories, biomanufacturing suites, and research suites to health science service providers, educational facilities, and pharmaceutical manufacturers. For more information, please visit www.biologicsmodular.com.
Forward Looking Statements: Statements in this document contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are based on many assumptions and estimates and are not guarantees of future performance. These statements may involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Positron Corporation to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Positron assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Our actual results may differ materially from the results anticipated in these forward-looking statements due to a variety of factors, including, without limitation those set forth as "Risk Factors" in our filings with the Securities and Exchange Commission.
SOURCE Positron Corporation